Insider Selling: Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Sells 5,100 Shares of Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CFO Matt Zuga sold 5,100 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $1.97, for a total transaction of $10,047.00. Following the completion of the transaction, the chief financial officer owned 222,644 shares in the company, valued at approximately $438,608.68. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Matt Zuga also recently made the following trade(s):

• On Wednesday, January 7th, Matt Zuga sold 5,805 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.99, for a total transaction of $11,551.95.
• On Monday, January 5th, Matt Zuga sold 4,000 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.96, for a total transaction of $7,840.00.

Acumen Pharmaceuticals Stock Performance

NASDAQ ABOS traded up $0.03 during trading hours on Wednesday, reaching $1.99. The company’s stock had a trading volume of 220,171 shares, compared to its average volume of 159,170. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.29. The business has a 50-day simple moving average of $1.96 and a 200 day simple moving average of $1.67. Acumen Pharmaceuticals, Inc. has a 52 week low of $0.86 and a 52 week high of $2.46. The stock has a market cap of $120.53 million, a PE ratio of -0.90 and a beta of 0.23.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its earnings results on Wednesday, November 12th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.19. Equities research analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ABOS. Jacobs Levy Equity Management Inc. bought a new position in Acumen Pharmaceuticals in the 3rd quarter valued at about $27,000. Marex Group plc acquired a new stake in shares of Acumen Pharmaceuticals in the 2nd quarter worth approximately $39,000. AQR Capital Management LLC acquired a new stake in shares of Acumen Pharmaceuticals in the 1st quarter worth approximately $46,000. Qube Research & Technologies Ltd boosted its holdings in shares of Acumen Pharmaceuticals by 160.0% in the second quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company’s stock valued at $67,000 after acquiring an additional 35,424 shares in the last quarter. Finally, Invesco Ltd. increased its stake in shares of Acumen Pharmaceuticals by 544.1% during the first quarter. Invesco Ltd. now owns 127,798 shares of the company’s stock valued at $141,000 after acquiring an additional 107,956 shares during the period. Institutional investors own 71.01% of the company’s stock.

Key Headlines Impacting Acumen Pharmaceuticals

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Neutral Sentiment: No stated reason in filings — The disclosures show routine Form 4 sales but do not explain whether trades were pre‑planned or for personal liquidity/diversification; that ambiguity leaves market interpretation open.
• Negative Sentiment: CEO Daniel Joseph O’Connell sold a total of 47,506 shares across Jan. 5–7 (individual trades of 4,649; 5,102; and 37,755 shares), receiving about $94.3k in proceeds; the largest single trade (37,755 shares) was reported as a 5.74% reduction in his stake. Read More.
• Negative Sentiment: CFO Matt Zuga sold 14,905 shares over Jan. 5–7 (4,000; 5,100; 5,805), totaling roughly $29.4k in proceeds and small single‑trade ownership reductions (1.73%–2.61%). Read More.
• Negative Sentiment: COO Russell Barton sold 9,318 shares over Jan. 5–7 (4,000; 3,618; 1,700), raising about $18.4k and reducing his stake by small single‑trade percentages (1.32%–2.94%). Read More.
• Negative Sentiment: Insider Eric Siemers sold 10,834 shares on Jan. 5–6 (4,000; 6,834), for about $21.3k in proceeds and reported ownership reductions of ~2.35%–4.11% per trade. Read More.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Bank of America dropped their price objective on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Acumen Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $6.75.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.